Ishita Drugs and Industries Ltd. is an established Indian manufacturer of **Active Pharmaceutical Ingredients (APIs)** and **drug intermediates**. Operating from its integrated facility in **Sanand, Ahmedabad**, the company serves leading domestic pharmaceutical firms and maintains a growing export presence. The company is currently navigating a pivotal strategic transition, shifting from financial consolidation toward a major infrastructure expansion aimed at high-margin niche products and global regulatory compliance. --- ### **Core Product Portfolio and Revenue Drivers** The company operates under a single business segment: the **"Pharmaceutical Business."** Revenue is primarily driven by three key product categories classified under the **ITC Code** system: | Product Description | ITC Code | Primary Application | | :--- | :--- | :--- | | **NORFLOXACIN** | **29419060** | Fluoroquinolone antibiotic | | **NICOTINIC ACID** | **29362920** | Vitamin B3 / Lipid-lowering agent | | **SULFONAMIDES** | **29359015** | Synthetic antimicrobial agents | The company is increasingly focusing on **low-volume, high-margin niche products** and **Specialty Chemicals** to differentiate itself from bulk commodity manufacturers. --- ### **Strategic Infrastructure Upgradation: Revised Schedule M** The company is currently executing a comprehensive renovation of its **Sanand facility** to comply with the **Revised Schedule M** (Good Manufacturing Practices) of the **Drugs and Cosmetics Act, 1940**. This is the most critical strategic initiative in the company’s current lifecycle. * **Project Scope:** Dismantling legacy production areas, constructing a new warehouse block, and installing modernized utilities and equipment. * **Financial Commitment:** As of **February 2026**, the company has incurred approximately **₹65 lakhs** on civil work and **₹100 lakhs** on capital expenditure. * **Regulatory Timeline:** The company is working under an extension to the **December 31, 2025** deadline. * **Strategic Objective:** Post-upgradation, the company aims to secure **WHO-GMP Certification**, which will serve as a gateway to **regulated and semi-regulated export markets** and facilitate the introduction of sophisticated new molecules. --- ### **Financial Performance and Capital Structure** The company recently achieved its **highest-ever total revenue**, rebounding from a post-COVID industry downturn. This growth was catalyzed by a **59.78% surge in exports**. **Three-Year Financial Summary:** | Metric (₹ in Crore) | FY 2023-24 | FY 2022-23 | FY 2021-22 | | :--- | :--- | :--- | :--- | | **Total Revenue** | **15.47** | **12.27** | **14.20** | | **Operating Profit** | **1.19** | **0.96** | **1.20** | | **Net Profit (PAT)** | **0.75** | **0.58** | **0.81** | | **Export Revenue** | **2.94** | **1.84** | - | **Key Financial Indicators:** * **Growth Momentum:** Revenue increased by **26.03%** year-on-year in the latest period. * **Profitability:** Net Profit increased by **29.62%** in the most recent cycle; **EPS** stands at **₹1.93**. * **Asset Composition:** As of March 31, 2023, **Current Assets** stood at **₹10.18 Crore**, significantly outweighing **Net Fixed Assets** of **₹0.89 Crore**, though this ratio is shifting as capital expenditure on the Sanand facility accelerates. * **Solvency:** The company has historically maintained a low-debt profile but has sought shareholder approval to increase borrowing limits to **₹30 Crores** to fund ongoing expansions. --- ### **Research, Development, and Innovation** The company maintains a dedicated R&D laboratory focused on **Process Development**, **Analytical Methods**, and **Chemical Synthesis**. * **Yield Improvement:** A primary focus is driving better margins through in-house process innovation and yield optimization. * **Technology Absorption:** The company relies entirely on **indigenous technology**, with **zero imported technology** over the last five years. * **Future Diversification:** Plans are underway to explore the **Biotechnology** sphere and initiate commercial production of newly developed **Specialty Chemicals**. * **R&D Investment Trends:** | Financial Year | Recurring Expenditure (₹) | % of Total Turnover | | :--- | :--- | :--- | | **2024-25** | **2,68,137** | **0.17%** | | **2023-24** | **1,78,115** | **0.12%** | | **2022-23** | **1,64,698** | **0.13%** | --- ### **Operational Efficiency and Sustainability** The company monitors utility consumption as a key operational metric to manage costs in a high-inflation environment. **Power and Fuel Consumption Data:** | Metric | 2024-25 | 2023-24 | 2022-23 | | :--- | :--- | :--- | :--- | | **Electricity Purchased (KWH)** | **56,632** | **54,572** | **72,898** | | **Total Electricity Cost (₹)** | **6,12,530** | **6,32,658** | **7,71,673** | | **Average Rate per Unit (₹)** | **10.82** | **11.59** | **10.59** | | **Other Fuels (₹)** | **14,13,676** | **9,50,987** | **9,26,276** | **Green Energy Initiative:** To mitigate rising power costs and improve sustainability, the company commissioned a **29.43 KW Roof Top Solar Power Plant**. --- ### **Ecosystem and Related Party Dynamics** The company leverages a network of related parties to complement its manufacturing and trading capabilities. Transactions with these entities often exceed **10% of annual turnover**. * **Ishita Pharmaceuticals (IP):** Focuses on drugs, excipients, and intermediates with a product range distinct from the company. * **Anvi Lifesciences Private Limited (ALPL):** Specializes in **finished dosage formulations** and trading APIs. --- ### **Risk Factors and Market Challenges** * **Regulatory Execution Risk:** Failure to meet **Revised Schedule M** standards within the government-mandated timeframe could jeopardize the license to manufacture. * **Import Dependency:** Approximately **60-70%** of APIs consumed in India are imported (primarily from China), creating a highly competitive pricing environment. * **Production Disruption:** Ongoing civil construction at the Sanand site may cause temporary fluctuations in manufacturing output. * **Resource Scarcity:** The company faces challenges in securing **skilled manpower** and **knowledge resources** required for high-tech pharmaceutical manufacturing. * **Environmental Compliance:** Stringent pollution control norms require continuous capital investment and operational oversight.